The Protocol Specific Research Support (PSRS) of the UNM Cancer Center functions to support early phase investigator-initiated pilot studies that lack sponsored support. Early phase unsupported investigator-initiated clinical trials are proposed at the Clinical Working Group level, and reviewed by the Protocol Review Committee (at UNM termed the Medical and Scientific Review Committee) for scientific merit. Should they be approved at this level, and lack support, they are submitted to the Clinical Research Committee for consideration of institutional support. This PSRS review is chaired by C. Verschraegen, MD, the member of the Clinical Research Committee responsible for organizing PSRS evaluations. Should the unsupported protocols be deemed worthy of support, they are then submitted to an appropriate IRB, and if approved, implemented by the Clinical Protocol, Data Management, and Informatics Shared Resource with protocol specific financial support. The PSRS research nurse is M. Pruess, and the data manager is M. Allred. In FY 2008/9 there were 19 investigator-initiated Phase l-lll interventional clinical trials that required UNM Cancer Center support. These trials accrued 222 total patients in the FY 2008/9. In FY 2008/9 there were 11 investigator-initiated phase I or l/ll interventional clinical trials that were supported by the UNM Cancer Center. These trials accrued 52 total patients. These trials were innovative pilot projects that were designed to lead to larger externally supported later phase clinical trials. This significant UNM Cancer Center support of early phase investigator-initiated clinical trials demonstrates an active Protocol Specific Research Support program.
Developing effective new cancer therapies is important since the survival of many patients with cancer is still poor. Not all new therapies are financially supported, especially those developed individually by UNM Cancer Center clinical investigators. The Protocol Specific Research support mechanism provides support for new cancer treatments that have no other financial support. This increases the number of new treatments that can be tested here.
| Zheng, Handong; Wu, Dandan; Wu, Xiang et al. (2018) Leptin Promotes Allergic Airway Inflammation through Targeting the Unfolded Protein Response Pathway. Sci Rep 8:8905 |
| Ray, Anita L; Berggren, Kiersten L; Restrepo Cruz, Sebastian et al. (2018) Inhibition of MK2 suppresses IL-1?, IL-6, and TNF-?-dependent colorectal cancer growth. Int J Cancer 142:1702-1711 |
| Hudson, Laurie G; Gillette, Jennifer M; Kang, Huining et al. (2018) Ovarian Tumor Microenvironment Signaling: Convergence on the Rac1 GTPase. Cancers (Basel) 10: |
| Licon-Munoz, Yamhilette; Fordyce, Colleen A; Hayek, Summer Raines et al. (2018) V-ATPase-dependent repression of androgen receptor in prostate cancer cells. Oncotarget 9:28921-28934 |
| Palsuledesai, Charuta C; Surviladze, Zurab; Waller, Anna et al. (2018) Activation of Rho Family GTPases by Small Molecules. ACS Chem Biol 13:1514-1524 |
| Sallmyr, Annahita; Tomkinson, Alan E (2018) Repair of DNA double-strand breaks by mammalian alternative end-joining pathways. J Biol Chem 293:10536-10546 |
| Kumar, Suresh; Jain, Ashish; Farzam, Farzin et al. (2018) Mechanism of Stx17 recruitment to autophagosomes via IRGM and mammalian Atg8 proteins. J Cell Biol 217:997-1013 |
| Vicuña, Belinda; Delaney, Harold D; Flores, Kristina G et al. (2018) Preferences for multigene panel testing for hereditary breast cancer risk among ethnically diverse BRCA-uninformative families. J Community Genet 9:81-92 |
| Feng, Bing; Hoskins, William; Zhang, Yan et al. (2018) Bi-stream CNN Down Syndrome screening model based on genotyping array. BMC Med Genomics 11:105 |
| Phinney, Brandon B; Ray, Anita L; Peretti, Amanda S et al. (2018) MK2 Regulates Macrophage Chemokine Activity and Recruitment to Promote Colon Tumor Growth. Front Immunol 9:1857 |
Showing the most recent 10 out of 344 publications
